SCHEMBL5160725

SCHEMBL5160725

NC(=O)CC(=O)c1ccsc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.54
CES1 P23141 1/20 0.54
LCK P06239 1/20 0.52
FYN P06241 1/20 0.52
DAO P14920 1/20 0.52
HDAC1 Q13547 2/20 0.52
HSD11B1 P28845 1/20 0.47
DPP4 P27487 3/20 0.46
HPGD P15428 1/20 0.44
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
KCNK3 O14649 1/20 0.39
KCNK9 Q9NPC2 1/20 0.39
ALOX5 P09917 1/20 0.39
HTR1A P08908 2/20 0.38
GPR52 Q9Y2T5 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
IKBKE Q14164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22721318 0.87 CES1 (0.62) CES2CES1LCKFYNDAO
SCHEMBL4336119 0.82 LCK (0.59) CES2CES1LCKFYNDAO
SCHEMBL3041357 0.80 CES2 (0.54) CES2CES1LCKFYNDAO
SCHEMBL1877973 0.79
SCHEMBL4771815 0.79
SCHEMBL15988683 0.79 CES2 (0.62) CES2CES1LCKFYNDAO
SCHEMBL22721312 0.78 HPGD (0.65) CES2CES1LCKFYNDAO
Hydrochloric Acid SCHEMBL9864723 0.78 CES2 (0.56) CES2CES1LCKFYNDAO
SCHEMBL5163099 0.77 CES2 (0.50) CES2CES1LCKFYNDAO
SCHEMBL4446977 0.77 CES2 (0.50) CES2CES1LCKFYNDAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO CES2 441/4885CES1 382/4885LCK 2902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.